Boston Scientific Acquires B. Braun's Anastomotic Leak Solutions Eso-SPONGE and Endo-SPONGE to Expand Endoscopic Portfolio

Sep 07, 2024 22:15 CST Updated 22:15

Boston Scientific

Medical Device Manufacturer

B. Braun

Developer and Manufacturer of Medical and Pharmaceutical Equipment

Boston Scientific announces the acquisition of two products from B. BraunAnastomotic Leak Solutions Products. These two products are respectivelyEso-SPONGE(Products used for the treatment of upper gastrointestinal anastomotic fistulas and perforations) andEndo-SPONGE(Used for the treatment of colorectal anastomotic fistula).

Anastomotic leakage of the upper/lower digestive tract is a serious postoperative complication. According to clinical statistics:

The incidence of anastomotic leakage after esophagectomy is as high as30%，And the relevant morbidityAnd the mortality rate is very high;
Up to 19% of patients are diagnosed with anastomotic leakage after colorectal surgery.

The complications of these two surgeries are one of the biggest challenges currently faced by clinicians. At present, the management of anastomotic leakage in the lower digestive tract mainly involvesAntibiotics and transrectal irrigation and drainage, such asIf effective results cannot be obtainedControl, then debridement and permanent stoma surgery are required. This is what patients do not want to see. There are relatively fewer solutions for upper gastrointestinal anastomotic leakage.

Facing this dilemma, B. Braun in this centuryInitialDeveloped outEndoluminal Vacuum Therapy (E-VAC) technology was initially applied to the treatment and prevention of anastomotic leakage in the digestive tract.Subsequently, B. Braun applied this technology to the upper gastrointestinal tract.Treatment and Prevention of Anastomotic Leakage.B. Braun discovered through clinical researchEndoluminal Vacuum Therapy (E-VAC) technology not only effectively prevents anastomotic leakage but alsoInAfter the occurrence of anastomotic leakageCan accelerate healing and avoid secondary surgery.

Boston Scientific AcquisitionB. BraunEndoluminal Vacuum Therapy (E-VAC) technology not only enriches its product line for endoscopic treatment but also expands its business into new fields. Addressing anastomotic leakage is currently a focus for many innovative companies and traditional giants, such as Johnson & Johnson, Nanjing Minimally Invasive, and Gians Medical, which have launched (or invested in) related therapeutic products. This will also become a new growth point for future surgical (gastroenterology) businesses.

Eso-SPONGE

Eso-SPONGEIt is an Endoluminal Vacuum Therapy (E-VAC) technology used to treat anastomotic insufficiency or perforations in the upper gastrointestinal tract.

Eso-SPONGEMade from porous polyurethane sponge, the polyurethane sponge is connected to a 100 cm long drainage tube at the end. It is designed to be installed in a cavity and, when connected to a vacuum pump, can drain, clean, and reduce the cavity.

Eso-SPONGE Treatment Principle:

WhenPolyurethaneEsterSponge is implanted into the patient's body.When,By applying negative pressure, effective continuous drainage can be achieved, therebyContinuously drain the fluid from the cavity, control infection, and clean the cavity (ClearFibrin), promote the growth of healthy tissue granulation, and mechanically reduce the size of the lumen.

Eso-SPONGESelf2014YearListed, A large amount of clinical research data has proven throughEso-SPONGE is used to treat anastomotic leaks in the upper digestive tract and can effectively promote the healing of the anastomosis.

Endo-SPONGE

Endo-SPONGESimilar to Eso-SPONGE, it is also an Endoluminal Vacuum Therapy (E-VAC) technology, but with different intended uses.Endo-SPONGEUsed to treat anastomotic insufficiency or perforation in the lower gastrointestinal tract.

Endo-SPONGESimilar to Eso-SPONGE, it is made of porous polyurethane sponge, with a 100 cm long drainage tube connected at the tail of the sponge. It is designed for placement within a cavity and, when connected to a vacuum pump, can drain, clean, and reduce the size of the cavity.

In additionEndo-SPONGEThe treatment principle of Eso-SPONGE is the same.

Endo-SPONGEInFirst used in 2008 for the treatment of rectal anastomotic fistulas, with over 40 clinical research papers published to date.

Advantages of Eso-SPONGE and Endo-SPONGE Treatment

Continuous drainage of infected wound fluid from the cavity;
Compared with irrigation, the treatment time is significantly shortened;
The median treatment duration was 20-50 days;
The anastomotic leakage closure rate reached 67-100%;
Outpatient treatment can be performed;
Reduce hospital stay;
Endo-SPONGReduce the rate of permanent stomas;
Reduce the number of repeat surgeries.

Boston Scientific

Boston Scientific Corporation transforms lives and improves the health of patients around the world through innovative medical technologies.As a global leader in medical technology for over 40 years, we provide a wide range of high-performance solutionsTo meet unmet patient needs and reduce healthcare costs, thereby advancing the life sciences.Its product portfolio helps doctors diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases and conditions.